Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society

Tool Details

  • Tool name: MCF7/TAMR-4 Cell Line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF7 S0.5
  • Organism: Human
  • Tissue: Breast
  • Cancer type: Breast cancer, tamoxifen-resistant
  • Disease: Cancer
  • Conditional: Yes
  • Description: The MCF7/TAMR-4 Cell line is a breast cancer cell line resistant to tamoxifen. Tamoxifen is by far the most widely used drug for hormone-dependent breast cancer. However, primary or acquired resistance to Tamoxifen severely limits its clinical effectiveness. The MCF7/TAMR-4 cell line is a good model cell to study the signalling pathways which are the major drivers of tamoxifen-resistant growth.
  • Research area: Cancer ; Drug Discovery & Development

  • For Research Use Only

Target Details

Application Details

Handling

  • Format: Frozen
  • Passage number: Passage 402 (AL3482), 403 (AL2753)
  • Growth medium: 37°C under 5% CO2 in air using phenol red-free DMEM:Ham’s F-12 F-12 containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 ?M).
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

  • Available on request

References

  •   Joshi et al. 2016. Oncotarget. :. PMID: 27528030.
  •   Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
  •   Elias et al. 2015. Oncogene. 34(15):1919-27. PMID: 24882577.
  •   Thrane et al. 2014. Oncogene. PMID: 25362855.
  •   A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
  •   Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
  •   Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
  •   Estrogen receptor a is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.
  •   Cutrupi et al. 2012. Oncogene. 31(40):4353-61. PMID: 22249258.
  •   Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
  •   Millour et al. 2010. Oncogene. 29(20):2983-95. PMID: 20208560.
  •   FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
  •   Pancholi et al. 2008. Endocr Relat Cancer. 15(4):985-1002. PMID: 18824559.
  •   ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
  •   Sarwar et al. 2006. Endocr Relat Cancer. 13(3):851-61. PMID: 16954434.
  •   Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression.